50 related articles for article (PubMed ID: 23489074)
1. A future perspective on the development of chemokine receptor CXCR4 antagonists.
Tamamura H; Tsutsumi H; Nomura W; Tanaka T; Fujii N
Expert Opin Drug Discov; 2008 Oct; 3(10):1155-66. PubMed ID: 23489074
[TBL] [Abstract][Full Text] [Related]
2. Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent.
Tamamura H; Fujisawa M; Hiramatsu K; Mizumoto M; Nakashima H; Yamamoto N; Otaka A; Fujii N
FEBS Lett; 2004 Jul; 569(1-3):99-104. PubMed ID: 15225616
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.
Tamamura H; Fujii N
Expert Opin Ther Targets; 2005 Dec; 9(6):1267-82. PubMed ID: 16300475
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents.
Tsutsumi H; Tanaka T; Ohashi N; Masuno H; Tamamura H; Hiramatsu K; Araki T; Ueda S; Oishi S; Fujii N
Biopolymers; 2007; 88(2):279-89. PubMed ID: 17167792
[TBL] [Abstract][Full Text] [Related]
5. Exploratory studies on development of the chemokine receptor CXCR4 antagonists toward downsizing.
Tamamura H; Tsutsumi H; Nomura W; Fujii N
Perspect Medicin Chem; 2008 Feb; 2():1-9. PubMed ID: 19787093
[TBL] [Abstract][Full Text] [Related]
6. Development of low molecular weight CXCR4 antagonists by exploratory structural tuning of cyclic tetra- and pentapeptide-scaffolds towards the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.
Tamamura H; Tsutsumi H; Masuno H; Fujii N
Curr Med Chem; 2007; 14(1):93-102. PubMed ID: 17266570
[TBL] [Abstract][Full Text] [Related]
7. Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs.
Tamamura H; Tsutsumi H; Masuno H; Mizokami S; Hiramatsu K; Wang Z; Trent JO; Nakashima H; Yamamoto N; Peiper SC; Fujii N
Org Biomol Chem; 2006 Jun; 4(12):2354-7. PubMed ID: 16763678
[TBL] [Abstract][Full Text] [Related]
8. Fluorescent CXCL12AF647 as a novel probe for nonradioactive CXCL12/CXCR4 cellular interaction studies.
Hatse S; Princen K; Liekens S; Vermeire K; De Clercq E; Schols D
Cytometry A; 2004 Oct; 61(2):178-88. PubMed ID: 15382150
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of the T140-based pharmacophores leads to the development of more potent and bio-stable CXCR4 antagonists.
Tamamura H; Hiramatsu K; Mizumoto M; Ueda S; Kusano S; Terakubo S; Akamatsu M; Yamamoto N; Trent JO; Wang Z; Peiper SC; Nakashima H; Otaka A; Fujii N
Org Biomol Chem; 2003 Nov; 1(21):3663-9. PubMed ID: 14649897
[TBL] [Abstract][Full Text] [Related]
10. Azamacrocyclic metal complexes as CXCR4 antagonists.
Tanaka T; Narumi T; Ozaki T; Sohma A; Ohashi N; Hashimoto C; Itotani K; Nomura W; Murakami T; Yamamoto N; Tamamura H
ChemMedChem; 2011 May; 6(5):834-9. PubMed ID: 21312334
[TBL] [Abstract][Full Text] [Related]
11. Peptide and peptidomimetic ligands for CXC chemokine receptor 4 (CXCR4).
Oishi S; Fujii N
Org Biomol Chem; 2012 Aug; 10(30):5720-31. PubMed ID: 22517031
[TBL] [Abstract][Full Text] [Related]
12. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003.
Abraham M; Biyder K; Begin M; Wald H; Weiss ID; Galun E; Nagler A; Peled A
Stem Cells; 2007 Sep; 25(9):2158-66. PubMed ID: 17525235
[TBL] [Abstract][Full Text] [Related]
13. CXCR4-derived synthetic peptides inducing anti-HIV-1 antibodies.
Hashimoto C; Nomura W; Narumi T; Fujino M; Nakahara T; Yamamoto N; Murakami T; Tamamura H
Bioorg Med Chem; 2013 Nov; 21(22):6878-85. PubMed ID: 24119449
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and in vitro evaluation of 68Ga-DOTA-4-FBn-TN14003, a novel tracer for the imaging of CXCR4 expression.
Hennrich U; Seyler L; Schäfer M; Bauder-Wüst U; Eisenhut M; Semmler W; Bäuerle T
Bioorg Med Chem; 2012 Feb; 20(4):1502-10. PubMed ID: 22264762
[TBL] [Abstract][Full Text] [Related]
15. Structure-based development of antagonists for chemokine receptor CXCR4.
Zhang C; Hou T; Feng Z; Li Y
Curr Comput Aided Drug Des; 2013 Mar; 9(1):60-75. PubMed ID: 22734712
[TBL] [Abstract][Full Text] [Related]
16. The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model.
Menu E; Asosingh K; Indraccolo S; De Raeve H; Van Riet I; Van Valckenborgh E; Vande Broek I; Fujii N; Tamamura H; Van Camp B; Vanderkerken K
Haematologica; 2006 May; 91(5):605-12. PubMed ID: 16627256
[TBL] [Abstract][Full Text] [Related]
17. [Multiple talents of the chemokine receptor-CXCR4].
Desjardins SF; Berchiche YA; Haddad E; Heveker N
Med Sci (Paris); 2007 Nov; 23(11):980-4. PubMed ID: 18021711
[TBL] [Abstract][Full Text] [Related]
18. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells.
Murakami T; Maki W; Cardones AR; Fang H; Tun Kyi A; Nestle FO; Hwang ST
Cancer Res; 2002 Dec; 62(24):7328-34. PubMed ID: 12499276
[TBL] [Abstract][Full Text] [Related]
19. Role of CXCR4 in HIV infection and its potential as a therapeutic target.
Murakami T; Yamamoto N
Future Microbiol; 2010 Jul; 5(7):1025-39. PubMed ID: 20632803
[TBL] [Abstract][Full Text] [Related]
20. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development.
Zou YR; Kottmann AH; Kuroda M; Taniuchi I; Littman DR
Nature; 1998 Jun; 393(6685):595-9. PubMed ID: 9634238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
